Johnson & Johnson (JNJ) Acquisitions (2009 - 2026)
Johnson & Johnson (JNJ) posted Acquisitions of -$17.2 billion for Q2 2026, down 198.5% sequentially from $17.5 billion in Q1 2026, and down 219.22% YoY from $14.5 billion in Q2 2025.
Johnson & Johnson (JNJ) Acquisitions (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Acquisitions for 18 years, with the latest figure at -$17.2 billion in Q2 2026.
- Quarterly Acquisitions fell 219.22% year-over-year to -$17.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.3 billion (down 79.67% YoY) and the FY2025 annual result came in at $17.5 billion, up 15.54% from the prior year.
- Acquisitions declined to -$17.2 billion in Q2 2026 per JNJ's latest filing, from $17.5 billion in the prior quarter.
- Over five years, Acquisitions peaked at $17.7 billion in Q1 2023 and troughed at -$17.2 billion in Q2 2026.
- A 5-year average of $3.6 billion and a median of $1.8 billion in 2024 frame the typical range for Acquisitions.
- The sharpest annual moves came in 2025 and 2026: Acquisitions soared 304000.0% in 2025, then tumbled 219.22% in 2026.
- Over 5 years, Acquisitions stood at $252.0 million in 2022, then jumped by 653.97% to $1.9 billion in 2023, then sank by 99.95% to $1.0 million in 2024, then jumped by 304000.0% to $3.0 billion in 2025, then tumbled by 666.82% to -$17.2 billion in 2026.
- According to Business Quant data, Acquisitions over the past three periods registered -$17.2 billion, $17.5 billion, and $3.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.59 Bn | 632.83 Bn | 17.26 Bn | -17.24 Bn |
| 2 | AbbVie | 470.48 Bn | 463.91 Bn | 12.70 Bn | - |
| 3 | Merck | 375.12 Bn | 367.98 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 302.96 Bn | 295.27 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.26 Bn | 252.36 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.14 Bn | 223.15 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 182.99 Bn | 179.82 Bn | 6.22 Bn | 11.21 Bn |
| 8 | Pfizer | 160.23 Bn | 148.53 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.11 Bn | 101.94 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.21 Bn | 47.83 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -17.24 Bn |
| Mar 29, 2026 | 17.50 Bn |
| Dec 28, 2025 | 3.04 Bn |
| Sep 28, 2025 | 1.00 Mn |
| Jun 29, 2025 | 14.46 Bn |
| Dec 29, 2024 | 1.00 Mn |
| Sep 29, 2024 | 1.80 Bn |
| Jun 30, 2024 | 1.80 Bn |
| Mar 31, 2024 | 1.81 Bn |
| Dec 31, 2023 | 1.90 Bn |
| Jan 1, 2023 | 17.65 Bn |
| Apr 3, 2022 | 252.00 Mn |
| Jan 3, 2021 | 6.37 Bn |
| Jun 28, 2020 | 800.00 Mn |
| Mar 29, 2020 | 939.00 Mn |
| Dec 29, 2019 | 4.91 Bn |
| Sep 29, 2019 | 216.00 Mn |
| Jun 30, 2019 | 3.40 Bn |
| Mar 31, 2019 | 1.68 Bn |
| Sep 30, 2018 | 675.00 Mn |